Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Aligos Therapeutics (ALGS) Stock Price & Analysis
53 Followers
ALGS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.84 - $2.41
Previous Close$1.11
Volume23.72K
Average Volume (3M)394.89K
Market Cap
$47.44M
Enterprise Value-$67.17M
Total Cash (Recent Filing)$125.83M
Total Debt (Recent Filing)$12.57M
Price to Earnings (P/E)-0.5
Beta1.54
Next Earnings
May 08, 2023EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding42,940,089
10 Day Avg. Volume63,752
30 Day Avg. Volume394,894
Standard Deviation0.31
R-Squared0.20
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.83
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$4.00Price Target Upside250.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Aligos Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $0.84 and its highest was $2.41 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Currently, no data Available
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is May 08, 2023 which is in 40 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on Mar 09, 2023. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.01.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate is -$0.47.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 39,723,255 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Among the largest hedge funds holding Aligos Therapeutics’s share is Versant Venture Management, LLC. It holds Aligos Therapeutics’s shares valued at 2M.
---
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (250.05% Upside)
$4.00 (250.05% Upside)
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.39%
12-Months-Change
Fundamentals
Return on Equity
-66.55%
Trailing 12-Months
Asset Growth
-37.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
---
Top 5 ETFs holding ALGS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold ALGS. The ETFs are listed according to market value of ALGS within the ETF
---
Synaptogenix
―
Protara Therapeutics
―
Unity Biotechnology
―
MAIA Biotechnology, Inc.
―
Avrobio
―
---